Your browser doesn't support javascript.
loading
Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial.
Mittal, Monica; McEniery, Carmel; Supramaniam, Prasanna Raj; Cardozo, Linda; Savvas, Mike; Panay, Nick; Hamoda, Haitham.
Afiliação
  • Mittal M; Imperial College Healthcare NHS Trust, St Mary's and Hammersmith Hospitals, Department of Obstetrics and Gynaecology, Praed Street, London W2 1NY. Electronic address: monica.mittal@nhs.net.
  • McEniery C; University of Cambridge, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, Hills Road, Cambridge CB2 0QQ.
  • Supramaniam PR; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Department of Obstetrics and Gynaecology, Headley Way, Headington, Oxford OX3 9DU.
  • Cardozo L; King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS.
  • Savvas M; King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS.
  • Panay N; Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Foundation Trust, Queen Charlotte's and Chelsea Hospital, Department of Obstetrics and Gynaecology, Du Cane Rd, White City, London W12 0HS.
  • Hamoda H; King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS.
Maturitas ; 161: 18-26, 2022 07.
Article em En | MEDLINE | ID: mdl-35688490
OBJECTIVE: To compare the difference between micronised progesterone (MP) and medroxyprogesterone acetate (MPA) in combination with transdermal oestradiol (t-E2) on cardiovascular disease (CVD) risk markers in women diagnosed with an early menopause and premature ovarian insufficiency (EMPOI). BACKGROUND: The European Society for Cardiology has identified carotid femoral pulse wave velocity (cfPWV) as the gold standard cardiogenic biomarker for risk stratification of arterial disease. Menopause has been shown to augment the age-dependent increase in arterial stiffness, with hormone replacement therapy (HRT) being the mainstay of management of women diagnosed with EMPOI. STUDY DESIGN: A pilot randomised prospective open-label trial. Women were randomised to either cyclical MP (Utrogestan® 200mg) or MPA (Provera® 10mg) in conjunction with t-E2 (Evorel® Patches 50mcg/day) for 12 months. Seventy-one subjects were screened, and baseline data are available for 57 subjects. MAIN OUTCOME MEASURE: Carotid-femoral pulse wave velocity (cfPWV). RESULTS: PWV did not significantly change from baseline in either treatment arm. MP + t-E2 demonstrated a positive effect on traditional CVD markers, with a significant improvement seen in cardiac output (CO) (0.71±1.01mL/min, 95% CI 0.20 to 1.21) and reduction in diastolic blood pressure (DBP) (-3.43±6.31mmHg, 95% Cl -6.57 to -0.29) and total peripheral resistance (TPR) (-0.15±0.19mmHg⋅min⋅mL-1, 95% CI -0.24 to -0.05) after 12 months. MPA + t-E2, in contrast, did not demonstrate significant changes from baseline in traditional haemodynamic parameters. CONCLUSION: The positive changes in traditional markers were not reflected in the cardiogenic biomarker, cfPWV, which has demonstrated a higher positive predictive value for cardiovascular events than traditional measurements.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Menopausa Precoce / Doenças Cardiovasculares / Insuficiência Ovariana Primária Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Maturitas Ano de publicação: 2022 Tipo de documento: Article País de publicação: Irlanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Menopausa Precoce / Doenças Cardiovasculares / Insuficiência Ovariana Primária Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Maturitas Ano de publicação: 2022 Tipo de documento: Article País de publicação: Irlanda